Cardio Diagnostics Holdings Stock EBITDA
| CDIO Stock | USD 0.53 0.04 7.02% |
Cardio Diagnostics Holdings fundamentals help investors to digest information that contributes to Cardio Diagnostics' financial success or failures. It also enables traders to predict the movement of Cardio Stock. The fundamental analysis module provides a way to measure Cardio Diagnostics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Cardio Diagnostics stock.
Cardio |
Cardio Diagnostics Holdings Company EBITDA Analysis
Cardio Diagnostics' EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a measure of a company operating cash flow based on data from the company income statement and is a very good way to compare companies within industries or across different sectors. However, unlike Operating Cash Flow, EBITDA does not include the effects of changes in working capital.
Current Cardio Diagnostics EBITDA | (1.53 M) |
Most of Cardio Diagnostics' fundamental indicators, such as EBITDA, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Cardio Diagnostics Holdings is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
In a nutshell, EBITDA is calculated by adding back each of the excluded items to the post-tax profit, and can be used to compare companies with very different capital structures.
| Competition |
According to the company disclosure, Cardio Diagnostics Holdings reported earnings before interest,tax, depreciation and amortization of (1.53 Million). This is 100.17% lower than that of the Biotechnology sector and 101.53% lower than that of the Health Care industry. The ebitda for all United States stocks is 100.04% higher than that of the company.
Cardio EBITDA Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Cardio Diagnostics' direct or indirect competition against its EBITDA to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Cardio Diagnostics could also be used in its relative valuation, which is a method of valuing Cardio Diagnostics by comparing valuation metrics of similar companies.Cardio Diagnostics is currently under evaluation in ebitda category among its peers.
Cardio Fundamentals
| Return On Equity | -2.93 | ||||
| Return On Asset | -0.98 | ||||
| Operating Margin | (162.96) % | ||||
| Current Valuation | 21.75 M | ||||
| Shares Outstanding | 40.44 M | ||||
| Shares Owned By Insiders | 9.86 % | ||||
| Shares Owned By Institutions | 4.14 % | ||||
| Number Of Shares Shorted | 1.53 M | ||||
| Price To Book | 6.24 X | ||||
| Price To Sales | 587.93 X | ||||
| Revenue | 17.07 K | ||||
| Gross Profit | 39.14 K | ||||
| EBITDA | (1.53 M) | ||||
| Net Income | (8.38 M) | ||||
| Cash And Equivalents | 9.66 M | ||||
| Cash Per Share | 5.08 X | ||||
| Total Debt | 1.26 M | ||||
| Current Ratio | 18.42 X | ||||
| Book Value Per Share | 0.14 X | ||||
| Cash Flow From Operations | (5.67 M) | ||||
| Short Ratio | 0.70 X | ||||
| Earnings Per Share | (0.30) X | ||||
| Target Price | 2.0 | ||||
| Beta | 4.68 | ||||
| Market Capitalization | 23.01 M | ||||
| Total Asset | 4.46 M | ||||
| Retained Earnings | (14.37 M) | ||||
| Working Capital | 1.92 M | ||||
| Net Asset | 4.46 M |
About Cardio Diagnostics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Cardio Diagnostics Holdings's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Cardio Diagnostics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Cardio Diagnostics Holdings based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with Cardio Diagnostics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Cardio Diagnostics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Cardio Diagnostics will appreciate offsetting losses from the drop in the long position's value.Moving together with Cardio Stock
Moving against Cardio Stock
| 0.74 | DTIL | Precision BioSciences | PairCorr |
| 0.71 | VIGL | Vigil Neuroscience | PairCorr |
| 0.62 | VINC | Vincerx Pharma | PairCorr |
| 0.58 | DNLI | Denali Therapeutics | PairCorr |
| 0.58 | DRRX | Durect | PairCorr |
The ability to find closely correlated positions to Cardio Diagnostics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Cardio Diagnostics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Cardio Diagnostics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Cardio Diagnostics Holdings to buy it.
The correlation of Cardio Diagnostics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Cardio Diagnostics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Cardio Diagnostics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Cardio Diagnostics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Cardio Diagnostics Piotroski F Score and Cardio Diagnostics Altman Z Score analysis. You can also try the Equity Forecasting module to use basic forecasting models to generate price predictions and determine price momentum.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cardio Diagnostics. If investors know Cardio will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Cardio Diagnostics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Cardio Diagnostics is measured differently than its book value, which is the value of Cardio that is recorded on the company's balance sheet. Investors also form their own opinion of Cardio Diagnostics' value that differs from its market value or its book value, called intrinsic value, which is Cardio Diagnostics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Cardio Diagnostics' market value can be influenced by many factors that don't directly affect Cardio Diagnostics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Cardio Diagnostics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Cardio Diagnostics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cardio Diagnostics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.